CNS orphan focus Target opportunities in rare CNS disorders and orphan brain conditions where Noema Pharma is actively developing novel therapies, aligning outreach with unmet patient needs and potential partnerships or licensing deals.

Phase 2 validation Leverage recent Phase 2a results in vasomotor symptoms to initiate discussions with CNS-focused investors, CROs, and strategic collaborators interested in actionable mid-stage data to de-risk collaboration or co-development opportunities.

Senior leadership growth Engage with Noema’s newly appointed CFO and EVP of R&D to position value propositions around capital efficiency, clinical development timelines, and potential partnerships that optimize their funding trajectories and milestones.

Strategic funding signals Capitalize on the Series B1 extension and substantial funding to propose joint ventures, research collaborations, and milestone-based deals with larger biotechs seeking CNS innovation pipelines and access to Noema’s platform.

Global biotech alignment Align outreach with Noema’s Basel, Switzerland and global research footprint, highlighting cross-border collaboration, manufacturing scalability considerations, and potential access to European and US grant or funding programs.